Why I’d ditch buy-to-let property and buy these 2 FTSE 100 growth shares today

I think that these two FTSE 100 (INDEXFTSE:UKX) shares could offer long-term growth potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With house prices being close to record levels when compared to average incomes, the capital growth potential of buy-to-let investments may be somewhat limited.

By contrast, the FTSE 100 appears to offer significant long-term growth prospects. A number of its members trade on fair valuations, and are expected to post improving financial performances as they deliver on their strategies.

Here are two prime examples of such companies. Buying them now could be a worthwhile move, since they may outperform buy-to-let investments in the coming years.

AstraZeneca

The recent third-quarter update from AstraZeneca (LSE: AZN) highlighted the rapid pace of growth that the FTSE 100 pharmaceutical company is experiencing. Its core earnings increased by 36% in the quarter compared to the same period of the prior year. This highlights the success of its strategy, with the company’s pipeline suggesting that a rapid rate of growth may be maintained over the long run.

As a result of its improving financial performance, the stock now trades on a price-to-earnings (P/E) ratio of around 27. While this may seem to be high, the stock is forecast to post a rise in its bottom line of 20% next year. This could justify its current valuation – especially since its balance sheet and cash flow provide the financial firepower it needs to maintain a high level of investment in its pipeline.

AstraZeneca’s defensive characteristics may appeal to investors in 2020. The company’s financial performance is less dependent on the wider economy than is the case for many of its FTSE 100 peers. As such, now could be the right time to buy a slice of it, with its current growth strategy set to lead to an improving share price performance.

Burberry

Another FTSE 100 share that has a solid growth strategy is Burberry (LSE: BRBY). The premium fashion business has changed its senior management team in the last few years, and is embarking on major strategy shifts that seem to be working well.

For example, it is working to move even more upmarket, is cutting costs, has launched a wide range of new products under its new creative head that are proving popular with consumers, and is seeking to boost its sales through the use of social media and influencers. Its focus on its highest-end  luxury products also involves store closures and store upgrades, all of it potentially leading to improving financial performance.

Although Burberry’s share price now trades on a P/E ratio of 24, it is forecast to produce a 10% rise in net profit next year. Beyond this, its exposure to fast-growing consumer markets across Asia could strengthen its investment appeal. Therefore, while there may be cheaper stocks available in the FTSE 100, the company’s financial prospects and its economic moat that is derived from a high degree of brand loyalty could lead to significant capital growth in the coming years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca and Burberry. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Grey cat peeking out from inside a cardboard box in a house
Investing Articles

Just released: April’s latest small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

The Anglo American share price soars to £25, but I’m not selling!

On Thursday, the Anglo American share price soared after mega-miner BHP Group made an unsolicited bid for it. But I…

Read more »

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »